CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
OTR mural celebrates UC alumni success
April 4, 2025
The UC Alumni Association, UCAA, will mark its annual Alumni Celebration during its upcoming Alumni Week, April 7-13, with a community art project commemorating this year’s slate of alumni honorees receiving the organization’s top awards.
Study: Platform-predicted treatments improve outcomes for...
April 4, 2025
Results from a new Phase 3 trial published in the journal npj Precision Oncology found that an assay that includes an assessment of cancer stem cell sensitivity to chemotherapy can accurately decide more effective treatments and lead to increased outcomes for patients with platinum-resistant ovarian cancer.
Pediatrician celebrates 30th UC College of Medicine reunion with...
April 3, 2025
There’s a vital thread woven into the fabric of Chris Peltier’s life. It’s black and red, and it knits all things Bearcat together into a life that was transformed by the University of Cincinnati and the UC College of Medicine.